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Abstract The presented studies were aimed at exploring the
role of neutral endopeptidase (NEP) in the function of colon
cancer cell lines LS 180 and SW 620, derived from different
grades and stages of tumor development. NEP silencing by
siRNA resulted in decreased viability and proliferation ac-
companied by increased apoptosis in both cell lines.
Additionally, cell cycle arrest at the G2/M phase was ob-
served, but only in LS 180 cells. Opposite to these results,
serum-stimulated migration was increased in both cell lines.
Furthermore, NEP silencing influenced the invasive activity
of LS 180 and SW 620 cells in an opposite manner: while LS
180 cells showed an enhanced invasiveness, SW 620 cells
exerted a reduced activity. An exploration of the activity of
signaling molecules responsible for the function of tumor
cells—Akt, PTEN, and FAK—after NEP silencing indicated
that the endopeptidase is involved in their regulation. The
increased phosphorylation level of Akt was accompanied by
a decrease in PTEN in the presence of a high concentration of
serum. A reduced concentration of serum did not change the
phosphorylation status of Akt. Enhanced autophosphorylation
of FAK was observed in LS 180 and SW 620 cells cultivated
in a medium with a high concentration of serum. Taken
together, these results confirm that NEP is implicated in the
regulation of the survival, growth, and motile activity of colon
cancer. This is also the first report which shows that NEP
mediates cancer cell migration and invasiveness, but not
growth and survival, through Akt/FAK signaling pathways.
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Introduction
In tumor cells, survival and proliferation, inhibition of apopto-
sis, invasion and migration, as well as the induction of angio-
genesis during carcinogenesis, are regulated by autocrine and
paracrine growth factors, cytokines, hormones, and signaling
peptides. The availability of these extracellular signaling mol-
ecules is regulated through proteolysis, which may be medi-
ated among others by cell membrane-bound peptidases,
expressed on the surface of tumor and stromal cells. One of
such peptidases is neutral endopeptidase (NEP), also called
neprilysin, enkephalinase, CD10, EC 3.4.24.11, and common
acute lymphoblastic leukemia antigen (CALLA) [1, 2]. NEP
could be a very useful tool for the diagnosis and prognosis of
B-lineage acute lymphoblastic leukemia and several carcino-
mas originating from the kidney, lung, skin, pancreas, pros-
tate, liver, breast, stomach, cervix, and bladder. It has been
determined that NEP can be up or downregulated in neoplastic
cells. Moreover, it should be underlined that the expression
level of NEP is dependent on the proliferation and differenti-
ation status of tumor cells. NEP is implicated both indirectly
and directly in the regulation of signaling pathways. Its indi-
rect action involves proteolytic degradation or activation of
bioactive peptides, growth factors, and cytokines. In addition
to this, NEP regulates signaling pathways in a direct fashion.
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This peptidase acts as a receptor anchored in the membrane
through GPI complexes. Studies have shown that CD10
(NEP) is implicated in cell migration, cell proliferation, and
survival through FAK and PTEN/Akt signaling pathways in
prostate cancer (PC) [1–6].
The phosphatase and tensin homolog detected on chromo-
some ten phosphatidylinositol-3,4,5-trisphosphate 3-
phosphatase (PTEN) acts as a tumor suppressor by antagoniz-
ing the activity of PI-3 kinase. PTEN dephosphorylates the
secondary messenger phosphatidylinositol 3,4,5-triposphate
(PIP3). This, in turn, results in the downregulation of the Akt
kinase activity. Akt is a pivotal molecule in the oncogenic
pathway which promotes cell growth, survival, and invasive-
ness [7]. PTEN is frequently inactivated in different manners
in a number of cancers, which results in an increased activity
of Akt and tumor progression [8, 9]. It should be underlined
that PTEN exerts its tumor-suppressive activity also by regu-
lating cell cycle and cell differentiation [10, 11].
Focal adhesion kinase (FAK) is a tyrosine kinase whose
activity is tightly connected with cell adhesion to the extracel-
lular matrix through integrin receptors. The regulation of
FAKs influences cellular events that are either dependent on
cell adhesion, such as cell proliferation and survival, or that
require modulation of cell adhesion, such as cell migration.
Involvement of FAKs in the cellular pathways which regulate
cell growth and cell movement implicates it in the develop-
ment of cancer and other diseases [12].
Colon carcinoma (CC) is one of the most prevalent tumors
in the world. The life expectancy of patients with a metastatic
form of this tumor has been extended in the past decade, but
the disease still remains incurable. The development of CC,
which starts with changes in a normal colonic epithelium
through adenomatous polyps to metastatic cancer, is depen-
dent on and supported by the tumor microenvironment. In the
case of CC, information about the role of tumor-associated
NEP is rather scanty. There are reports which indicate that this
peptidase contributes to liver metastasis of CC cells by
degrading the antitumoral peptide, Met-enkephalin [13, 14].
Most studies consider the expression levels of NEP proteins in
the tissue samples of colon adenocarcinoma in comparison
with adjacent non-neoplastic tissues and with respect to the
degree of tumor differentiation, tumor development, progres-
sion to more advanced stages, invasion, and metastasis. The
studies are discrepant in some aspects. De Oliveira et al. and
Sato et al., for instance, have reported that the level of NEP
expression was higher in CC tissue samples than in non-
neoplastic mucosa adjacent to the tumor, whereas Ogawa
et al. did not find any expression of this marker in samples
of normal tissue [15–17]. Sato et al. and Fujimoto et al. iden-
tified a higher expression level of NEP in well or/and moder-
ately differentiated adenocarcinoma tissue specimens in com-
parison with poorly differentiated ones [16, 18]. On the other
hand, de Oliveira et al. and Oshima et al. did not observe any
differences in NEP expression corresponding to histological
differentiation [15, 19]. Lymphatic, vascular, and/or perineu-
ral invasion of colorectal carcinoma was associated with NEP
expression according to Fujimoto et al. and Yao et al., whereas
de Oliveira et al. and Fujita et al. did not observe any signif-
icant relationships in this respect [15, 18, 20, 21]. Moreover,
there are some controversies regarding the expression level of
the peptidase and metastasis. Fujimoto et al. and Yao et al.
have identified a strong expression of this marker in patients
with a higher incidence of liver metastases [18, 21]. On the
other hand, de Oliveira et al. and Fujita et al. did not find any
such relationship [15, 20].
In the present study, we examined the role of NEP in
the function of CC cells derived from different grades (II
and IV) and stages (B and C according to Duke’s classi-
fication) of tumor development and presenting high levels
of NEP expression. Moreover, we investigated the role of




The human colon cancer cell lines obtained from the
American Type Culture Collection (ATCC), HT-29 (no.
HTB-38), LS 180 (no. CL-1870), SW 948 (no. CCL-237),
and SW 620 (no. CCL-227), were used in these studies.
These cell lines represented different grades and stages of
cancer development (Duke’s classification): HT-29 (Duke’s
stage A, grade I), LS 180 (Duke’s stage B, grade II), SW
948 (Duke’s stage C, grade III), and SW 620 derived from a
lymph node metastatic site of tumor (Duke’s stage C, grade
IV). They were maintained in appropriate media recommend-
ed by ATCC, namely, HT-29 in McCoy’s 5A medium, LS180
in MEM, and SW948 and SW620 in Leibovitz’s L-15 medi-
um. All media were supplemented with fetal calf serum (FCS)
at different concentrations, depending on study requirements,
plus 100 U/ml penicillin and 100 μg/ml streptomycin. Cell
cultures were cultivated under standard conditions at 37 °C,
95 % humidity and with (HT-29 and LS 180) or without (SW
948 and SW 620) 5 % CO2.
NEP gene expression silencing
Inhibition of NEP gene expression was achieved by RNA
interference with short interfering RNA (siRNA) against hu-
man NEP. Silencer® Select siRNA targeted to the NEP gene
(siNEP) and negative control siRNA (siCtrl) were purchased
from Invitrogen™ (Thermo Fisher Scientific). At first, three
different siRNAs were tested to determine which of them pro-
vide the highest level of NEP silencing. Ultimately, the sense
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sequence of siNEP CGGCUAUCCUGAUGACAUUtt and
the antisense sequence AAUGUCAUCAGGAUAGCCGat
were used in studies. A non-siRNA control (cells not treated
with siRNA) was also included in these studies. Depending on
assay requirements, transfection was performed in 6-well
plates, T25 flasks, or Lab-Tek™ microscope slides. In these
experiments, two-step transfection (reverse transfection
followed by forward transfection) was used which allowed
us to achieve the best level of NEP silencing. As the first step
of silencing, we diluted siRNA in Opti-MEM® I medium in
cell cultureware. Then, Lipofectamine™ RNAiMax was
added. The mixture was incubated for 20 min at room tem-
perature (RT). Next, LS 180 and SW 620 cells were
suspended in a culture medium supplemented with FCS with-
out antibiotics. The LS 180 cell line was used at a density of
7.5×104 cells/ml and SW 620 at 8.5×104 cells/ml. Cells were
added to complexes of siRNA and Lipofectamine™
RNAiMax, mixed gently, and then incubated for 24 h under
standard conditions. After that, forward transfection was con-
ducted. In this step, siRNA and Lipofectamine™ RNAiMax
were diluted in Opti-MEM® Imedium separately, mixed gent-
ly, and incubated for 5 min at RT. Next, they were combined,
mixed, and incubated for 20 min at RT. Complexes of siRNA
and Lipofectamine™ RNAiMax were added to cells and in-
cubated for 24 h. After this, colon cancer cells were subjected
to further assays. In each step of transfection, siRNAwas used
at 10 nM of final concentration combined at a 1:1 volume ratio
with a lipid carrier. The effectiveness of gene silencing was
determined by immunofluorescence staining and flow cytom-
etry as described below.
Immunofluorescence detection of NEP
Immunofluorescence staining was performed to determine
the presence of NEP in the colon cancer cell lines. For this
purpose, cells were cultivated on Lab-Tek™ microscope
slides (Chamber Slide™ Systems, Thermo Scientific) for
48 h under standard conditions and in the presence of 10 %
FCS. Afterward, cells were washed three times with PBS
and fixed for 10 min in 3.7 % paraformaldehyde in PBS.
After washing, cells were treated with 0.2 % Triton X-100
for 7 min and once again washed with PBS. Subsequently,
a blocking step in 5 % goat serum was performed for
30 min at RT. Cells were then incubated with mouse anti-
human NEP mAb (Santa Cruz Biotechnology, Inc.)
(1:250), washed with PBS, and incubated with goat anti-
mouse IgG-FITC secondary antibodies (Santa Cruz
Biotechnology Inc.) (1:500). Labeled cells were mounted
in Ul t r aCruz® Mount ing Med ium (San ta Cruz
Biotechnology Inc.) containing DAPI stain and examined
under the LSM 5 Pascal/AxioVert 200M confocal micro-
scope (Carl Zeiss). Negative control comprised cells incu-
bated with secondary antibodies alone.
Flow cytometry analysis of NEP expression
Fluorescence-activated cell sorting (FACS) was performed to
quantify the level of NEP in the colon cancer cell lines HT-29,
LS 180, SW 948, and SW 620. For this purpose, cells were
cultivated in six-well plates in the presence of 10 % FCS for
48 h under standard conditions. The cells were detached with
Accutase® Solution, resuspended in a medium with 1 % FCS,
and incubated for 60 min under standard conditions.
Afterward, cells were centrifuged at 300×g for 5 min and
washed with PBS. Then, cells were incubated with phycoer-
ythrin (PE)-conjugated mouse antihuman NEP mAb IgG (BD
Biosciences) for 30 min at RT in darkness. In addition to this
procedure, a permeabilization step was also incorporated to
enable intracellular staining of the cells. After washing with
PBS, FACS data, acquired by running the samples on a FACS
Calibur (BD Biosciences), were analyzed using Cell Quest
software (BD Biosciences). The data were expressed as per-
cent of cells expressing NEP and relative mean fluorescence
intensity (MFI). IgG isotype control Ab (BDBiosciences) was
used as a negative control.
In vitro viability assay
The viability of LS 180 and SW 620 colon cancer cells after
NEP silencing was determined by the Neutral Red uptake
assay (Tox-4, Sigma). For this purpose, cells cultivated in
T25 flasks were transfected as described above. After that,
the cells were harvested and plated in 96-well plates. For the
viability assay, 5.5×105 cells/ml (LS 180) and 8.5×105 cells/
ml (SW 620) were used. After the cells adhered, the cell cul-
ture medium was changed to one supplemented with 2 %
(restricted proliferation of the cells) FCS. The colon cancer
cells were incubated for 48 h. Afterward, the Neutral Red
uptake assay was performed according to the manufacturer’s
instruction. The viability of the cells was expressed as percent
of the non-siRNA control (100 % of living cells).
In vitro proliferation assay
The proliferation activity of LS 180 and SW 620 cells after
NEP silencing was established using a method based on the
incorporation of bromodeoxyuridine (BrdU) into the DNA of
actively proliferating cells and detection of the nucleotides by
specific antibodies coupled with an enzyme (ELISA) (Roche
Molecular Biochemicals). Transfection was performed in six-
well plates. After harvesting, the cells were plated in 96-well
plates at a density of 5.5 × 104 cells/ml (LS180) and
8.5×104 cells/ml (SW 620). Cells were cultivated in an ap-
propriate medium supplemented with 10 % (extensively pro-
liferating cells) FCS for 72 h. Additionally, in some experi-
ments, IL-8 (Cell Signaling Technology, Inc.) was added to
the culture medium at a final concentration of 10 ng/ml. After
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incubation, the BrdU assay was performed according to the
manufacturer’s instruction. The optical density was measured
at 570 nm by means of a Universal Plate Reader, EL800 (Bio-
Tek Instruments, Inc.). The proliferation activity of the colon
cancer cells after NEP silencing was expressed as percent of
the non-siRNA control (100 % of actively proliferating cells).
In vitro migration and invasion assays
The migration and invasiveness assays were performed in
transwells. The migration assay was conducted in transwells
equipped with membrane inserts (pore size, 8 μm) in 24-well
plates. The invasiveness of the colon cancer cells was assessed
based on the number of cells invading through the basement
membrane extract (BME)-coated membrane (8 μm) of
transwell chambers using the Trevigen’s CultureCoat® 96-
well Cell Invasion Assay (R&D Systems). The assay was per-
formed according to the manufacturer’s instruction with a mi-
nor modification. Prior to the assays, colon cancer cells were
starved in a medium supplemented with 0.5 % FCS overnight.
After that, LS 180 and SW 620 cells were harvested and
suspended in a medium with 2 % FCS to a density of
8.5×105 and 1.0×106 cells/ml, respectively. Cells were added
to the top chambers. Bottom chambers were filled with an
appropriate medium supplemented with 2 % FCS (no
chemoattractant gradient—spontaneous migration/invasion)
or 10 % FCS (a chemoattractant gradient—chemoattracted mi-
gration/invasion). After 72 h of incubation under standard con-
ditions, the number of colon cancer cells invading to the lower
surface of the insert membrane was quantified using Calcein
AM, which, after internalization into the cells, is processed to
free calcein. Free calcein fluoresces brightly. The fluorescence
was measured by means of a Perkin Elmer Victor™ plate
reader. The fluorescence obtained in the non-siRNA control
corresponded to 100 % of migration or invasion activity. The
results were expressed as percent of the non-siRNA control.
Apoptosis analysis
FACS along with a modified annexin V/propidium iodide pro-
tocol (FITC AnnexinV Apoptosis Detection Kit II, BD
Pharmingen™) were used to determine apoptosis (as percent
of total cell number) in colon cancer cells after NEP silencing.
Briefly, cells were cultivated in six-well plates in the presence
of 2 or 10 % FCS for 72 h under standard conditions after
transfection. After harvesting and suspending in annexin V
binding buffer, cells were incubated with annexin V and sub-
sequently with PI. After that, cells were permeabilized with
formaldehyde to promote entry of RNase into the cells follow-
ing staining. The addition of RNase (Sigma) limits the number
of false-positive events resulting from PI staining of RNAwith-
in the cytoplasm. FACS data were acquired on a FACS Calibur
(BD Biosciences) and analyzed using Cell Quest software (BD
Biosciences). The following controls were used: unstained
cells and cells stained with FITC Annexin Vor PI only.
Cell cycle analysis
LS 180 and SW 620 cells growing in six-well plates were
transfected as described above. After transfection, colon can-
cer cells were cultivated in a medium with 2 or 10 % FCS for
72 hours. Next, cells were harvested, washed with PBS, and
fixed overnight with 80 % ethanol at −20 °C. After that, cells
were washed with PBS and stained with a solution containing
PI and RNase for 30 min in darkness at RT. The cells were
analyzed by means of FACS Calibur (BD Biosciences) and
FACS data were processed using Cell Quest software (BD
Biosciences). The results were presented as percentage of cells
in phases G0/G1, S, and G2/M.
Western blot analysis
To extract total proteins, colon cancer cells were rinsed with
ice-cold PBS and lysed with RIPA buffer (Sigma) supple-
mented with a phosphatase inhibitor cocktail (Sigma) and a
protease inhibitor cocktail (Sigma) for 30 min on ice. Cells
were collected and centrifuged for 10 min at 14,000 rpm and
4 °C. Supernatants were collected, and total protein concen-
tration was determined by means of a method based on
bicinchoninic acid (Pierce® BCA Protein Assay Kit, Thermo
Scientific). Samples containing 50 μg were denatured and
separated by 10 % SDS-PAGE gel electrophoresis (Bio-Rad,
Mini-Protean® Tetra Cell). After that, proteins were trans-
ferred (Bio-Rad, Transfer-Blot® SD Semi-Dry Transfer Cell)
to a PVDF membrane (Millipore, Immubilom-P). The mem-
brane was incubated with blocking buffer (5 % non-fat dry
milk or BSA) in Tris-buffered saline (TBST) with 0.1 %
Tween-20, depending on the recommendation of the producer
of the primary antibodies used. After blocking, the mem-
branes were incubated with primary antibodies diluted in
TBST overnight at 4 °C. The primary antibodies were rabbit
anti-total FAK and anti-phospho (Tyr397 and 925) FAK, rab-
bit anti-total PTEN and anti-phospho (Ser380/Thr382/383)
PTEN, and rabbit anti-total Akt and anti-phospho (Thr308)
Akt (1:1000) (Cell Signaling Technology Inc.). To detect
phosphospecific antibodies, 0.01 % of the phosphatase inhib-
itor cocktail was added to the blocking buffer and the antibody
diluent. Afterward, the membranes were washed with TBST
three times and subjected to HRP-conjugated secondary anti-
bodies (goat anti-rabbit, Amersham™ GE Healthcare) for 1 h
at RT. Protein-antibody complexes were visualized with the
ECL™Western Blotting Analysis System (Amersham™ GE
Healthcare) and Molecular Imager® ChemiDoc™ XRS+
equipped with ImageLab™ software. The blots used to detect
the phosphorylated form of proteins were stripped and
reprobed with respective anti-total protein antibodies (Santa
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Cruz Biotechnology Inc.) as described above. β-actin (anti-β-
actin antibodies, Santa Cruz Biotechnology Inc., 1:500) was
also used as a load control. Additionally, protein molecular
markers (Precision Plus Protein™ Dual Color Standards)
were loaded onto electrophoretic gels to control the molecular
weight of the protein bands.
Results
Differential expression of NEP in colon cancer cell lines
The expression of NEP in colon cancer lines was
established by immunofluorescence staining and flow cy-
tometry. Microscopic analysis revealed that colon cancer
cells exhibited different patterns of NEP expression. LS
180 and SW 620 cell lines showed the most pronounced
fluorescence (Fig. 1). As can be seen in the confocal mi-
croscopy images, NEP was located peripherally. The flow
cytometry analysis demonstrated that SW620 cells, which
are metastatic colon cancer cells (Duke’s stage C; grade
IV) present in lymph nodes, showed the highest level of
NEP expression (92.5 %± 4.9; MFI 166 ± 28.56) (Fig. 2).
However, LS 180 cells, representing stage B of colon can-
cer according to Duke’s classification (grade II), also
strongly expressed NEP, as detected by flow cytometry
(91.8 % ± 3.7; MFI 118.6 ± 32.72). Additionally, it was
observed that in permeabilized cells before NEP detection,
the MFI value was higher by approximately 20 % in both
cell lines (data not presented).
NEP is involved in the regulation of proliferation
and metastatic activity of colon cancer cells
The function of NEP in the biology of colon cancer cells was
investigated in an experiment with LS 180 and SW 620 cell
lines, which had the highest levels of NEP expression. By
silencing NEP expression with specific siRNA, we were able
to examine the role of NEP as both a peptidase capable of
degrading biological active peptides and an immune receptor
anchored in the membrane through GPI complexes. In the
preliminary studies, three different siRNAs were tested
to achieve the highest level of NEP silencing (data not
presented). Ultimately, the sense sequence of siNEP
CGGCUAUCCUGAUGACAUUtt and the antisense sequence
AAUGUCAUCAGGAUAGCCGat were used in studies.
Immunofluorescence staining showed that siNEP caused NEP
silencing (Fig. 3a). Moreover, flow cytometry indicated that the
number of LS 180 cells and SW 620 cells with silenced NEP
was reduced by about 58 % (MFI was reduced by 42 %) and
50 % (MFI, 32 %), respectively (Fig. 3b). Silenced expression
of NEP resulted in a statistically significantly decreased viabil-
ity of both cell lines expressing high levels of neutral endopep-
tidase, namely, LS 180 and SW 620. A more pronounced
Fig. 1 Immunofluorescence staining of NEP in the indicated colon
cancer cell lines. Cells were indirectly labeled using mouse anti-human
NEP antibodies and FITC-conjugated goat anti-mouse IgG-FITC
secondary antibodies. The nuclei were stained with DAPI. Negative
control comprised cells incubated with secondary antibodies alone and
counterstained with DAPI. Representative photographs are shown in the
figure
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decrease was observed in the case of the metastatic cell line SW
620 (by 47%) compared with LS 180 (by 15%) (Fig. 4).When
the influence of silencing of CD10 expression was measured as
proliferation activity, a decrease was also observed. There were
no differences in the proliferation activity between the two
types of cells as measured by the BrdU assay (Fig. 5). All the
results were statistically significant in comparison with the non-
siRNA and siCtrl controls. Moreover, significant differences
were observed between the two cell lines when IL-8 was added
to the medium as an additional growth factor. Silencing of
CD10 in the LS 180 cell line decreased its proliferation activity
stimulated by the growth factor. In contrast, silencing of neutral
endopeptidase in SW 620 decreased spontaneous proliferation
but did not affect proliferation additionally stimulated by the
growth factor (Fig. 5).
In further experiments, the involvement of NEP in the
migration and invasive activity of LS 180 and SW 620 cell
lines was examined. As indicated in Fig. 6, silencing of
CD10 by siRNA did not influence spontaneous migration
of either cell line. On the other hand, enhanced serum-
stimulated migration was observed. It was especially pro-
nounced in the LS 180 cell line, which showed an about
50 % increase in migration activity in comparison to a cor-
responding non-siRNA control. To compare, the migration
activity of SW 620 increased by only 20 %. These results
were statistically significant. By contrast, measurement of
invasion activity using transwells coated with BME indi-
cated that silencing of NEP enhanced spontaneous and
serum-stimulated invasive activity only in the LS 180 cell
line (Fig. 7). Both spontaneous and stimulated activity were
increased by approximately 13 % in comparison to an ap-
propriate non-siRNA control. In contrast to that, in the SW
620 cell line, NEP silencing with siRNA strongly inhibited
spontaneous invasive activity (about 16 %) as well as
serum-stimulated activity (about 30 %) (Fig. 7). Both, the
increase and the decrease observed in the in vitro invasion
assay were statistically significant in comparison with ap-
propriate controls, as indicated in the figure.
Fig. 2 The expression profiles of
NEP in the HT-29, LS 180, SW
948, and SW 620 cell lines
characterized by flow cytometry.
Cells were labeled with PE-
conjugated mouse anti-human
NEP antibodies. R2 gates in dot
plots included NEP-positive cells.
The table presents the percent (%)
of NEP-positive cells and mean
fluorescence intensity (MFI). The
results are mean values (±SD) of
four independent experiments
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Silencing of NEP induces apoptosis and arrest of colon
cancer cells in the G2/M phase
As can be seen in Figs. 4 and 5, the viability and proliferation
of LS 180 and SW 620were significantly reduced by silencing
of NEP. We used flow cytometry to determine whether cell
death induction and/or an alteration in cell cycle may have
been responsible for these outcomes. The viability and prolif-
eration assays were carried out with medium supplemented
with 2 % (restricted proliferation of the cells) and 10 % (ex-
tensively proliferating cells) FCS, respectively. The apoptosis
and cell cycle analysis were also done at the same manner, to
reflect experiment conditions of viability and proliferation as-
says. We detected that RNAi led to apoptotic, but not to ne-
crotic cell death, in both cell lines. The level of necrosis was up
to 4 % in each sample (data not presented). NEP silencing in
LS 180 cells resulted in the presence of 40 and 18 % of apo-
ptotic cells in cell cultures cultivated with 2 and 10 % FCS,
respectively. SW 620 cell cultures contained about 14 % of
apoptotic cells independent of the concentration of serum
(Fig. 8). The increase in the number of apoptotic cells was
statistically significant in comparison with non-siRNA and
siCtrl. A flow cytometry analysis revealed that silencing of
NEP caused a cell cycle alteration in the LS 180 cell line but
not in SW 620. The former showed a significant decrease in
the number of cells in the G0/G1 phase. This was accompanied
by an increase in the number of LS 180 cells in the G2/M phase
(about 16 % in comparison to a non-siRNA control) (Fig. 9).
NEP is engaged in signal transduction via the Akt/PTEN
and FAK pathways
Akt/PKB and PTEN are parts of opposite-acting signaling
pathways that regulate cell growth and survival. In tumor cells,
including colon cancer cells, they are also responsible for the
migration and invasive activity, similarly to FAK [7, 8, 12,
22–28]. In this study, it was examined whether these signaling
pathways are mediated by NEP. The activity of Akt, PTEN,
and FAK was established by western blot analysis on the basis
of the level of phosphorylation of these proteins at specific
sites. The results were expressed as fold of differences (FDs)
in the phosphorylation level after NEP silencing (siNEP) and
cultivation of cell cultures in a medium with 2 % (restricted
proliferation of the cells) or 10 % (extensively proliferating
cells) FCS for 48 h in comparison to a control (1.0) (siCtrl).
The results were normalized to the β-actin level. The differ-
ences in the phosphorylation level of each protein in the non-
siRNA control and siCtrl were not statistically significant. The
densitometric analysis revealed that NEP silencing did not alter
the expression level of the examined proteins or did not result
in their degradation (total amount) but affected their phosphor-
ylation status, and hence, their activity and stability. First and
foremost, the results indicated that in comparison to the con-
trol, NEP silencing was followed by a statistically significant
Akt activation in LS 180 (FD 2.85) and, to some degree, in SW
620 (FD 1.5) cultivated in the presence of 10 % FCS. By
contrast, a low concentration of serum did not significantly
change the phosphorylation level of Akt (Fig. 10a). In both
of the examined cell lines, the increase in Akt phosphorylation
was accompanied by a strong, statistically significant decrease
Fig. 3 A decrease in NEP expression in the LS 180 and SW 620 cells after
transfection with siRNA against human NEP. a Immunofluorescence
staining of NEP. Cells were stained as indicated in Fig. 1. b The table
presents the percent (%) of NEP-positive cells and MFI estimated by
flow cytometry. The results are mean values (±SD) of all independent
analyses carried out
Fig. 4 A decrease in the viability of LS 180 and SW 620 cells 48 h after
NEP silencing, as determined by the Neutral Red uptake assay. The
results were expressed as percent of a non-siRNA control (100 % of
viable cells). The results are mean values (±SD) of three independent
experiments. Differences were considered statistically significant at
p< 0.05 (Student’s t test) in comparison with non-siRNA and siCtrl
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in PTEN phosphorylation (LS 180–FD 0.79; SW 620–FD
0.69). Opposite to Akt, PTEN exhibited a lowered phosphor-
ylation level in NEP-silenced cells cultivated in the 2 % FCS
medium (LS 180–FD 0.66; SW 620–FD 0.79) (Fig. 10b). NEP
silencing resulted in the differential patterns of FAK phosphor-
ylation at Tyr397 and 925 depending on the serum concentra-
tion in the medium and the cell line used (Fig. 11a, b).
Significantly decreased phosphorylation (FD 0.5 and 0.83)
was detected at Tyr397 in the LS 180 and SW 620 cell lines
cultivated in the medium supplemented with 2 % FCS. By
contrast, the presence of 10 % FCS significantly increased
phosphorylation in both cell lines (LS 180–FD 1.3; SW 620–
FD 1.48) (Fig. 11a). NEP silencing, exerted a significant effect
on the phosphorylation status of FAK at Tyr925 only in the LS
180 cell line. The effect was negative for the LS 180 cells
cultivated in the low serum-concentration medium, in compar-
ison to the control (FD 0.5), and positive for cells grown in the
medium with 10 % FCS (FD 1.4). In the case of SW 620 cells,
NEP silencing did not cause any significant changes in the
phosphorylation of FAK at Tyr925 (Fig. 11b).
Discussion
Colon cancer accounts for a significant part of human malig-
nancies. It is one of the most frequent causes of cancer deaths
in Western countries. Surgical resections remain the optimal
and often the only therapeutic option for this type of neoplasia,
with pharmacological treatments being far from satisfactory.
For those reasons, many research groups are prompted to ex-
plore the mechanisms of colorectal neoplasia and metastasis.
One of the most widely explored problems is the role of pro-
teases and peptidases of different origins, e.g., tumor- and
stroma-associated, in the development of malignancy and
Fig. 5 Inhibition of the proliferation of LS 180 and SW 620 cells
determined by the BrdU method 72 h after NEP silencing. Cell cultures
were cultivated in the presence of 10% FCS alone or 10% FCS plus IL-8
(10 ng/ml). The results were expressed as percent of a non-siRNA control
(100 % of actively proliferating cells). The results are mean values (±SD)
of three independent experiments. Differences were considered
statistically significant at p< 0.05 (Student’s t test) in comparison with
appropriate non-siRNA and siCtrl (*) or siNEP/10 % FCS (#)
Fig. 6 Changes in the migration activity of LS 180 and SW 620 cells
detected by the transwell method. Cells migrated spontaneously or
toward 10 % FCS, 72 h after NEP silencing. Colon cancer cells
migrated to the lower surface of transwell membranes were quantified
by measuring calcein AM fluorescence. The results were expressed as
percent of migrated cells in comparison with a non-siRNA control. The
results are mean values (±SD) of three independent experiments.
Differences were considered statistically significant at p < 0.05
(Student’s t test) in comparison with (asterisk) respective non-siRNA,
siCtrl, or siNEP (spontaneous) and (number sign) non-siRNA and siCtrl
(chemoattracted)
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metastasis. Few of these studies, however, implicate NEP, a
cell membrane-bound peptidase, in colon cancer development
and metastasis. Most reports evaluate only the relationship
between the expression level of the peptidase and the stage/
grade ormetastasis development of CC in vivo [15–21]. There
are some reports which implicate NEP in colon cancer metas-
tasis to the liver but not in biological functions of primary and
secondary tumors developing in other sites, e.g., lymph nodes
[13, 14]. Given this knowledge, it seemed worth to investigate
the role of tumor-associated NEP in the biology of colon can-
cer cells derived from diverse stages of tumor development
(LS180–Duke’s stage B, grade II and SW 620–Duke’s stage
C, grade IV) on the cellular and molecular level. To achieve
this aim, we used colon cancer cells with inhibited NEP gene
expression obtained by RNA interference with siRNA against
human NEP. The use of the silencing procedure enabled us to
investigate the role of NEP as both a peptidase capable of
degrading bioactive molecules and a receptor anchored in
the membrane through GPI complexes.
In the present study, we evaluated the presence
(immunostaining) and expression level (flow cytometry) of
NEP in colon cancer cells originating from different stages and
grades of tumor. The immunostaining pattern was consistent
with the flow cytometry results and indicated that LS180–
Duke’s stage B, grade II, and SW 620–Duke’s stage C, grade
IV, exhibited the highest levels of NEP compared to the other
Fig. 7 Changes in invasion of the LS 180 and SW 620 cells detected in a
transwell chamber assay using a basement membrane extract (BME)-
coated membrane (8 μm). Cells invaded spontaneously or toward 10 %
FCS, 72 h after NEP silencing. Colon cancer cells which invaded to the
lower surface of the transwell membranes were quantified by measuring
calcein AM fluorescence. The results were expressed as percent of
invaded cells in comparison with a non-siRNA control. The results are
mean values (±SD) of three independent experiments. Differences were
considered statistically significant at p < 0.05 (Student’s t test) in
comparison with (asterisk) respective non-siRNA, siCtrl, or siNEP
(spontaneous); (number sign) non-siRNA and siCtrl (chemoattracted)
and ±non-siRNA and siCtrl (spontaneous)
Fig. 8 Induction of apoptosis in the LS 180 and SW 620 cell cultures
after NEP silencing. Apoptotic cells (%) were detected by flow cytometry
and cell labeling with Annexin V/propidium iodide 72 h after
transfection. Cell cultures were cultivated in a medium supplemented
with 2 % FCS (a) or 10 % (b). The results are mean values (±SD) of
three independent experiments. Differences were considered statistically
significant at p< 0.05 (Student’s t test) in comparison with (asterisk) non-
siRNA and (number sign) siCtrl. Black arrows indicate bands
corresponding to pFAK
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colon cancer cell lines examined (HT-29–Duke’s stage A, grade
I and SW 948–Duke’s stage C, grade III). A microscopic anal-
ysis of the colon cancer cell lines revealed a peripheral (mem-
brane and cytoplasm) localization of NEP. Moreover, flow cy-
tometry showed that MFI was higher in permeabilized cells
(data not presented), which could also point to the cytoplasmic
localization of NEP. The same type of NEP localization has been
reported by Jang et al. [29]. Some results reported in the litera-
ture indicate that the expression of NEP is higher in well- and/or
moderately differentiated colon carcinomas but not in poorly
(metastatic) differentiated ones [16, 18]. On the other hand, there
is evidence that the NEP expression level is significantly higher
in invasive colon cancer tissue samples (lymphatic, vascular,
perineural, and liver invasion) than in lower-stage and non-
neoplastic specimens [18, 21, 29]. This difference may result
from the fact that in our study, cell lines and not tissue samples
were analyzed. Cell lines, due to being cultured for some time,
do not necessarily reflect parental tumor. But, considering our
results, we can state that there was no correlation between the
CD10 expression and the grade of cancer development. Further
experiments were performed using cell lines which exhibited the
highest level of NEP expression (LS 180 and SW 620). NEP
silencing by siRNA in these cell lines resulted in a significant
decrease in the expression of this protein, as indicated by
immunofluorescence staining and flow cytometry analysis.
The number of LS 180 cells with silenced NEP was reduced
by about 58 % (MFI reduced by 42 %) and the number of SW
620 cells by about 50 % (MFI reduced by 32 %).
The involvement of NEP in cell survival, growth, and
motility has been widely reported for non-neoplastic cells
and pancreatic tumor. In the case of the latter, the action of
the peptidase was coordinated with the PI3-K/Akt, PTEN,
Src, and FAK signaling pathways [2, 6]. There are also studies
showing that these signaling pathways mediate the function of
colon cancer cells [22–28]. Surprisingly, there are no reports
which would implicate NEP in the biology of colon cancer
cells in connection with the mentioned signaling pathways.
This prompted us to investigate the influence of NEP silencing
on colon cancer cell growth, proliferation, and motility.
Moreover, we examined whether these processes were
mediated by the Akt, PTEN, and FAK signaling pathways.
FAK is a non-receptor kinase which, after activation, is
autophosphorylated at Tyr397. This enables its binding of
diverse signaling molecules, among others Src or PI3K. As a
result of these interactions, FAK is phosphorylated at other
sites, e.g., Tyr925, what leads to its full activation and
regulation of the viability, proliferation, and motile activity
of the cells [12].
Fig. 9 The effect of NEP silencing on cell cycle distribution in the LS
180 and SW 620 cell cultures. Cells were cultured in a medium
supplemented with 2 % FCS (a) or 10 % (b) 72 h after transfection.
Cell cycle distribution was determined by flow cytometry and cell
staining with propidium iodide. The results are presented as percent of
cells in phase G0/G1, S, and G2/M and mean values (±SD) of three
independent experiments. Differences were considered statistically
significant at p < 0.05 (Student’s t test) in comparison with (asterisk)
non-siRNA and (number sign) siCtrl
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In preliminary experiments, we determined, for the first
time, that NEP is essential for the survival and growth of
LS 180 (Duke’s stage B, grade II) and SW 620 (Duke’s
stage C, grade IV) colon cancer cells. Peptidase silencing
was followed by a statistically significant decrease in the
viability and proliferation of these cells. Further studies
indicated, for the first time, that NEP silencing resulted in
apoptosis of both types of cells when they were cultured in
the presence of 2 % (viability assay) or 10 % (proliferation
assay) FCS. Moreover, our study is the first to observe that
NEP silencing leads to cell cycle arrest in colon cancer cell
lines. The arrest at G2/M phase was observed only in the
LS 180 cell culture under these culture conditions. Studies
on the involvement of NEP in colon cancer survival and
growth are scanty. The only report addressing this problem
is that by Luo et al., who found that growth of HT-29 cells
was inhibited after treatment with antisense phosphoro-
thioate oligodeoxynucleic acid (S-ODN) for CD10 [14].
Further studies on Akt, PTEN, and FAK activity using
Western blot analysis revealed that cultivation of NEP-
silenced colon cancer cells in the medium with 2 % (restricted
proliferation of cells) or 10 % (extensively proliferating cells)
FCS resulted in the diverse phosphorylation statutes of these
signaling molecules. This is probably caused by different
levels of growth factors in the medium. First, the cultivation
of cells in the medium with 2 % did not change the phosphor-
ylation level of Akt but decreased the phosphorylation levels
of PTEN and FAK (both at Tyr397 and Tyr925). According to
some reports, the decrease in PTEN phosphorylation should
have resulted in an increase in its activity and its rapid degra-
dation, but only in the membrane-associated form [8, 30]. No
such effects were observed in our study. The decreased phos-
phorylation of PTEN and FAK in NEP-silenced colon cancer
cells observed in our study may partially explain the un-
changed activity of Akt. However, the mechanism of inhibi-
tion of FAK phosphorylation in NEP-silenced colon cancer
cells needs to be further investigated. One clue for future stud-
ies is the suggestion that NEP-mediated regulation of FAK
and Akt activity involves PI3K and Src [6, 12, 22]. In contrast
to cultures done with 2 % FCS, cultivation of NEP-silenced
colon cancer cells in the medium with 10 % FCS resulted in a
significantly increased phosphorylation of Akt and FAK at
Tyr397 accompanied by the inhibition of PTEN. These results
are consistent with known mechanisms of crosstalk between
these signaling molecules. Even so, the activity levels of Akt,
PTEN, and FAK obtained in our study do not fully explain the
observed inhibition of survival and proliferation of cancer
cells, the induction of their apoptosis, and cell cycle arrest. It
Fig. 10 Changes in the phosphorylation of Akt (a) and PTEN (b) in the
LS 180 and SW 620 cells 48 h after NEP silencing. Cells were cultivated
in the presence of either 2 % FCS or 10 % FCS. Equal amounts of cell
extracts were immunoblotted with antibodies as indicated in the figure.
Anti-β-actin antibodies were used as load control. The left panel presents
representative blots and graphs show a densitometric analysis of the
bands. FD—fold of difference after normalization against β-actin and
in comparison with siCtrl. The densitometric analysis was performed on
the basis of three independent experiments, and the results are shown as
mean values (±SD). Differences were considered statistically significant
at p< 0.05 (Student’s t test) in comparison with siCtrl
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seems that other signaling pathways may contribute to these
effects. One possibility is that the NEP-mediated survival and
proliferation of colon cancer cells involves crosstalk among
the FAK, Src, and MAPK pathways. A decreased viability of
(among others) LS 180 and SW620 accompanied by inhibited
autophosphorylation of FAK (Tyr397) has been examined by
Heffler et al. [22]. Moreover, some researchers have reported
the induction of apoptosis in colon cancer cells with inhibited
FAK (Tyr397), Src, and Akt activities [22, 31]. The decreased
viability and induction of apoptosis accompanied by inhibited
FAK autophosphorylation is consistent with our results for LS
180 and SW 620 cells cultivated in the mediumwith 2% FCS.
The inhibition of cancer cell survival and proliferation, induc-
tion of apoptosis, and cell cycle arrest at G2/M observed in our
experiments may have also been an outcome of the activation
of the p38 MAPK pathway. It is known that activated FAK is
autophosphorylated at Tyr397 [32]. This enables Src binding
and subsequent phosphorylation of FAK by this kinase
(among others) at Tyr925. pTyr925FAK interacts with diverse
signaling molecules such as Grb2, which leads to the activa-
tion of the Ras-ERK signaling pathway and stimulation of
proliferation and cell cycle progress [33]. In our study, we
observed a decreased or an insignificantly changed
phosphorylation level of FAK at Tyr925, which was not coor-
dinated with FAK phosphorylation status at Tyr397. These
changes may have been a consequence of disturbed Src/
FAK interactions. Moreover, the changes we observed in the
phosphorylation status of FAK at Tyr925 may have caused
inhibition of ERK activation and a resultant activation of
p38 MAPK pathway. These processes could have led to the
induction of apoptosis and disturbances in the cell cycle [34,
35]. This hypothesis is supported by Luo et al.’s finding that
treatment of HT-29 cells with CD10 antisense S-ODN de-
crease phosphorylation of ERK1/2 and increased that of p38
MAPK [14].
The motility of cancer cells through the extracellular matrix
or the basement membrane plays an essential role in tumori-
genesis. Cancer cells can move spontaneously or toward a
chemoattractant gradient. Both types of movement enable me-
tastasis of the primary tumor. In our study, NEP silencing re-
sulted in an increased (chemoattracted) migration of both the
LS 180 and SW 620 cells. This was accompanied by an in-
creased phosphorylation of FAK at Tyr397 and Akt. The in-
volvement of FAK as a downstream target of Akt in colon
cancer cell migration has been investigated by Turečkova
et al. [28]. It seems likely that NEP silencing in LS 180 and
Fig. 11 Changes in the phosphorylation of FAK at Tyr397 (a) and
Tyr925 (b) in the LS 180 and SW 620 cells 48 h after NEP silencing.
Cells were cultivated in the presence of either 2 % FCS or 10 % FCS.
Equal amounts of cell extracts were immunoblotted with antibodies as
indicated in the figure. Anti-β-actin antibodies were used as a load
control. The left panel shows representative blots and graphs present a
densitometric analysis of the bands. FD—fold of difference after
normalization against β-actin and in comparison with siCtrl. The
densitometric analysis was performed on the basis of three independent
experiments, and the results are shown as mean values (±SD). Differences
were considered statistically significant at p < 0.05 (Student’s t test) in
comparison with siCtrl
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SW 620 led to an enhanced activity of PI3-K and subsequently
Akt. This resulted in FAK activation and increased migration.
Unexpectedly, the present study on the invasiveness activ-
ity of colon cancer cells derived from primary tumor (LS 180)
and metastatic lymph nodes (SW 620) revealed opposite roles
of NEP in these two cell lines. While NEP-suppressed LS 180
cells exhibited enhanced invasiveness through BME, both
spontaneous and toward a chemoattractant gradient, SW 620
cells showed decreased invasiveness under the same condi-
tions. We supposed that this disparity was probably due to the
different origins of the two cell lines. The different phenotypes
of LS 180 and SW 620 cells enable them to create an appro-
priate microenvironment. At this stage of studies, we cannot
explain the exact reason of these results. These issues require
further investigation.
In summary, our studies indicate that NEP is involved in
colon cancer cell growth, proliferation, and migration/inva-
siveness, independent of the stage/grade of tumor develop-
ment. Moreover, we have shown for the first time that NEP
mediates motile activities of colon cancer cells through Akt/
FAK signaling pathways but does not affect cell growth and
survival.
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